Page 8 - Thomasj Schall News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomasj schall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomasj Schall Today - Breaking & Trending Today

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

Share:
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
Avacopan safe and well tolerated in C3G patients
ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU
Conference call today at 4:30 pm Eastern Time ....

United States , Vifor Pharma , Stefan Schulze , Thomasj Schall , Swiss Stock Exchange , European Commission , Drug Administration , Swiss Exchange , Vifor Pharma Group , European Medicines Agency , Chemocentryx Inc , Fresenius Medical Care , Histologic Index , Disease Activity , Disease Chronicity , Vifor Fresenius Medical Care Renal Pharma , Glomerular Filtration Rate , Chief Executive Officer , European Patients , Activity Score , Fibrosis Progression , Kidney Function , Pharma Group , End Stage Renal Disease , Marketing Authorization Application , ஒன்றுபட்டது மாநிலங்களில் ,

VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
oaoa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oaoa.com Daily Mail and Mail on Sunday newspapers.

United States , Stephanie Tomei , Vifor Pharma , Julien Vignot , Susanm Kanaya , Dburns Mcclellan , Nathalie Ponnier , Stefan Schulze , Lee Roth , Thomasj Schall , Swiss Stock Exchange , European Commission , Drug Administration , Global Head Corporate Communications , Swiss Exchange , Exchange Commission , Vifor Pharma Group , European Medicines Agency , Chemocentryx Inc , Fresenius Medical Care , Fresenius Medical Care Renal Pharma , Chief Executive Officer , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , End Stage Renal Disease , Marketing Authorization Application ,

Vifor Fresenius Medical Care Renal Pharma: VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

(2)
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
Avacopan safe and well tolerated in C3G patients
ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005694/en/ ....

United States , Stephanie Tomei , Vifor Pharma , Julien Vignot , Susanm Kanaya , Dburns Mcclellan , Nathalie Ponnier , Stefan Schulze , Lee Roth , Thomasj Schall , Fresenius Medical , Swiss Stock Exchange , European Commission , Drug Administration , Global Head Corporate Communications , Swiss Exchange , Exchange Commission , Vifor Pharma Group , European Medicines Agency , Chemocentryx Inc , Fresenius Medical Care , Fresenius Medical Care Renal Pharma , Chief Executive Officer , Pharma Group , Vifor Fresenius Medical Care Renal Pharma , End Stage Renal Disease ,